ProShare Advisors
INDV icon

ProShare Advisors’s Indivior Pharmaceuticals INDV Stock Holding History

ProShare Advisors’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$867K Sell
21,129
-3,380
-14% -$123K ﹤0.01% 837
2026
Q1 		$747K Sell
24,509
-4,630
-16% -$153K ﹤0.01% 888
2025
Q4 		$1.05M Buy
29,139
+3,949
+16% +$121K ﹤0.01% 811
2025
Q3 		$607K Sell
25,190
-4,345
-15% -$90.9K ﹤0.01% 1017
2025
Q2 		$435K Buy
+29,535
New +$344K ﹤0.01% 1196

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ProShare Advisors's INDV Position: Q2 2026 in Review

ProShare Advisors reduced its Indivior Pharmaceuticals (INDV) stake by 14% in Q2 2026, selling an estimated $123K and leaving 21,129 shares worth $867K. The position accounts for ﹤0.01% of the portfolio, ranked #837.

ProShare Advisors first reported a position in INDV in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.05M in Q4 2025. 339 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • ProShare Advisors held 21,129 shares of Indivior Pharmaceuticals worth $867K as of Q2 2026.
  • ProShare Advisors sold 3,380 Indivior Pharmaceuticals shares in Q2 2026, an estimated $123K.
  • Indivior Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #837 holding.
  • ProShare Advisors first reported a position in Indivior Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • ProShare Advisors's Indivior Pharmaceuticals position peaked at $1.05M in Q4 2025.
  • 339 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.